DE69923687D1 - Verwendung von dem verstärker der glukosen aufnahme rosiglitazone zur verminderung der ischaemia-induzierte apoptose der pankreatischen betazellen, der endothelialen zellen und der neuronalen zellen - Google Patents

Verwendung von dem verstärker der glukosen aufnahme rosiglitazone zur verminderung der ischaemia-induzierte apoptose der pankreatischen betazellen, der endothelialen zellen und der neuronalen zellen

Info

Publication number
DE69923687D1
DE69923687D1 DE69923687T DE69923687T DE69923687D1 DE 69923687 D1 DE69923687 D1 DE 69923687D1 DE 69923687 T DE69923687 T DE 69923687T DE 69923687 T DE69923687 T DE 69923687T DE 69923687 D1 DE69923687 D1 DE 69923687D1
Authority
DE
Germany
Prior art keywords
betazelles
rosiglitazone
glossy
pancreatic
reinforcing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69923687T
Other languages
English (en)
Other versions
DE69923687T2 (de
Inventor
M A Bril
Edwin Buckingham
Nassirah Khandoudi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire GlaxoSmithKline SAS
SmithKline Beecham Ltd
Original Assignee
Laboratoire GlaxoSmithKline SAS
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Laboratoire GlaxoSmithKline SAS, SmithKline Beecham Ltd filed Critical Laboratoire GlaxoSmithKline SAS
Application granted granted Critical
Publication of DE69923687D1 publication Critical patent/DE69923687D1/de
Publication of DE69923687T2 publication Critical patent/DE69923687T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69923687T 1998-07-21 1999-07-21 Verwendung des Verstärkers der Glukoseaufnahme Rosiglitazon zur Verminderung der Ischämie-induzierten Apoptose der pankreatischen Betazellen, der endothelialen Zellen und der neuronalen Zellen Expired - Fee Related DE69923687T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GB9815872 1998-07-21
GB9815871 1998-07-21
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
GB9905387 1999-03-09
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (2)

Publication Number Publication Date
DE69923687D1 true DE69923687D1 (de) 2005-03-17
DE69923687T2 DE69923687T2 (de) 2006-04-06

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923687T Expired - Fee Related DE69923687T2 (de) 1998-07-21 1999-07-21 Verwendung des Verstärkers der Glukoseaufnahme Rosiglitazon zur Verminderung der Ischämie-induzierten Apoptose der pankreatischen Betazellen, der endothelialen Zellen und der neuronalen Zellen

Country Status (26)

Country Link
EP (2) EP1098639B1 (de)
JP (1) JP2002521326A (de)
KR (1) KR20010079551A (de)
CN (1) CN1310620A (de)
AP (1) AP2001002036A0 (de)
AT (1) ATE288746T1 (de)
AU (1) AU5053799A (de)
BG (1) BG105250A (de)
BR (1) BR9912117A (de)
CA (1) CA2338211A1 (de)
DE (1) DE69923687T2 (de)
DK (1) DK1098639T3 (de)
EA (1) EA200100165A1 (de)
ES (1) ES2237929T3 (de)
HK (1) HK1037865A1 (de)
HU (1) HUP0103199A3 (de)
ID (1) ID26986A (de)
IL (1) IL140664A0 (de)
NO (1) NO20010292L (de)
OA (1) OA11579A (de)
PL (1) PL345627A1 (de)
PT (1) PT1098639E (de)
SI (1) SI1098639T1 (de)
SK (1) SK1012001A3 (de)
TR (1) TR200100207T2 (de)
WO (1) WO2000004890A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
CA2265656A1 (en) * 1996-09-12 1998-03-19 Sankyo Company, Limited Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
ES2259459T3 (es) * 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
ES2237929T3 (es) 2005-08-01
AP2001002036A0 (en) 2001-03-31
NO20010292D0 (no) 2001-01-18
ATE288746T1 (de) 2005-02-15
ID26986A (id) 2001-02-22
AU5053799A (en) 2000-02-14
WO2000004890A1 (en) 2000-02-03
IL140664A0 (en) 2002-02-10
EP1098639A1 (de) 2001-05-16
EP1098639B1 (de) 2005-02-09
DK1098639T3 (da) 2005-06-13
DE69923687T2 (de) 2006-04-06
PL345627A1 (en) 2002-01-02
HUP0103199A3 (en) 2002-08-28
KR20010079551A (ko) 2001-08-22
HUP0103199A2 (hu) 2002-05-29
BG105250A (en) 2001-11-30
BR9912117A (pt) 2001-04-10
HK1037865A1 (en) 2002-02-22
JP2002521326A (ja) 2002-07-16
EP1516617A2 (de) 2005-03-23
OA11579A (en) 2004-06-01
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
PT1098639E (pt) 2005-06-30
CN1310620A (zh) 2001-08-29
CA2338211A1 (en) 2000-02-03
SI1098639T1 (de) 2005-08-31
EA200100165A1 (ru) 2001-08-27
TR200100207T2 (tr) 2001-05-21

Similar Documents

Publication Publication Date Title
DE69909029D1 (de) Kosmetisches oder dermopharmazeutisches Pflaster
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60235866D1 (de) Verwendung von speziellen Aminosilikonen zur Nachbehandlung in der direkten oder oxidativen Färbung von Keratinfasern
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
DE60005973D1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
DK2412368T3 (da) Sammensætning til behandling af ar
DE50100265D1 (de) Verwendung von Pfropfcopolymeren zur Herstellung lasergravierbarer Reliefdruckelementen
DE69905906D1 (de) Kombination von zwei oder mehreren wirkstoffen unter verwendung von mikrokapsel-formulierungen
DE1100751T1 (de) Herstellung von anionischen nanokompositen und ihre verwendung als retentions- und entwässerungshilfsmittel bei der papierherstellung
DE59902868D1 (de) Verwendung von ectoin oder ectoin-derivaten in formulierungen
EE200300165A (et) Fenofibraadi ja koensüüm Q10 kombinatsioon endoteeli düsfunktsiooni ravimiseks
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69825187D1 (de) Metallische Prothese zur Unterstützung und/ oder zum Ersatz von offenzelligem Gewebe
DZ2438A1 (fr) Atropisomères de 3-hétéroaryl-4(3h)-quinazolinones.
DE69915486D1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
DE69923687D1 (de) Verwendung von dem verstärker der glukosen aufnahme rosiglitazone zur verminderung der ischaemia-induzierte apoptose der pankreatischen betazellen, der endothelialen zellen und der neuronalen zellen
DE60005300D1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
DE69808866D1 (de) Herstellung von Titanschlacke
DE59910763D1 (de) Verwendung von ectoin oder ectoin-derivaten in kosmetischen formulierungen
DE69918953D1 (de) Zusammensetzung von oligosacchariden zur regulierung von apoptose
NO20010569D0 (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
ATE294853T1 (de) Verwendung von pit-emulsionen in fermentationsverfahren
DE59903541D1 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee